CAY10583 

CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds^[1].

CAY10583 (1 nM-1μM; 24 hours) promotes wound closure via keratinocyte migration. And CAY10583 has no significant effect of on keratinocyte proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAY10583 (administered topically to full-thickness wounds; 10 μM; 14 days) significantly results in a greater wound closure than the control group. The difference in wound closure between the CAY-treated group and the control group is pronounced over time until day 10. And the difference is approximately 6% at day 4 and reaches almost 20% at day 8. Notably, 100% closure was observed in the CAY-treated group at day 14^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

387.47

C₂₅H₂₅NO₃

862891-27-8

O=C(C1=CC=CC=C1C2=CC=C(C=C2)CN(C(CCCC)=O)C3=CC=CC=C3)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lin Luo, et al. A synthetic leukotriene B 4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J Diabetes Complications. 2017 Jan;31(1):13-20  [Content Brief]